Skip to main content

Day: January 8, 2021

Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule

MALVERN, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Listing Rule 5550(a)(2).Previously, on December 27, 2019, Nasdaq had notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. In order to regain compliance with Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. On September...

Continue reading

Orca Energy Group Inc. Announces Preliminary Financial and Operating Results for 2020

TORTOLA, British Virgin Islands, Jan. 08, 2021 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) announces its preliminary unaudited financial and operating results for 2020. All currency amounts in this news release are in United States Dollars ($) unless otherwise stated.FINANCIAL HIGHLIGHTSFor the year ended December 31, 2020, the Company’s:Average sales volumes for the year ended December 31, 2020 decreased 8.6% to 57.7 million standard cubic feet per day (“MMcfd”) compared to 63.1 MMcfd for the year ended December 31, 2019 and for Q4 2020 decreased 11.3% to 62.8 MMcfd compared to 70.8 MMcfd for Q4 2019. Reduced gas sales in 2020 were primarily attributed to the impact of the coronavirus pandemic on consumer investment/demand...

Continue reading

One World Universe Inc. Issues Corporate Update

HUNTINGTON BEACH, CA, Jan. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — One World Universe Inc. (OTC: OWUV), a holding company that invests in distressed assets and business opportunities within emerging industries, has issued a corporate update to its shareholders and potential new investors.The company was made aware there were rumors of a merger with Life on Earth, Inc. (OTC: LFER) circulating around social media. To bring clarity, management of J. Craig Holding Corp. (JCHC) have a working relationship with the present LFER CEO, Fernando Oswaldo Leonzo, in which this past summer, JCHC participated in a Preferred B private offering for 50,000 shares. These shares were placed into the public entity as an asset and announced via an amended press release on September 29, 2020.The later part of 2020 has been incredibly challenging...

Continue reading

Notice of fourth quarter and 2020 annual results and conference call 

Notice of fourth quarter and annual 2020 results and conference call Luxembourg, January 8, 2021 – Millicom will announce its fourth-quarter and annual 2020 results on February 11, 2021 at approximately 12:00 (Stockholm) / 11:00 (London) / 06:00 (Miami) via a press release.Millicom will host a conference call for the global financial community on February 11, 2021 at 14:00 (Stockholm) / 13:00 (London) / 08:00 (Miami).To access the live webcast visit this link.Analysts and investors who wish to participate in the Q&A session should pre-register using the following link. Those unable to pre-register may also join the interactive event by calling any of the following numbers:Sweden:          +46-8-5053-5281                                Luxembourg:  +352-8002-3716UK:                  +44-20-3795-9972                              US:      ...

Continue reading

Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM

MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM.Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited to give our first shareholder conference call to update investors about the development of our Ii-Key complete vaccine against the SARS-CoV-2 coronavirus that continues to ravage the world. We have completed our ex vivo human trial of COVID-19 patient samples and can confirm that the results of the T cell activation and antibody screen have enabled us to select Ii-Key-SARS-CoV-2 epitopes for our vaccine formulation. I will provide an update on these results as well as the results of our ongoing immunogenicity study that will confirm the...

Continue reading

Bessor Appoints New Auditor

NANAIMO, British Columbia, Jan. 08, 2021 (GLOBE NEWSWIRE) — Bessor Minerals Inc. (TSXV:BST) (“Bessor” or the “Company”) announced today that it has appointed Dale Matheson Carr-Hilton Labonte LLP as auditor of Bessor effective January 8, 2021. The resignation of Bessor’s former auditor, Crowe Mackay LLP, was accepted by the Company effective January 8, 2021.BESSOR MINERALS INC.Kieran Downes, Ph.D., P.Geo.President, CEO & Director

Continue reading

Photo Release — Huntington Ingalls Industries Announces New Vice President, Business Management, and Chief Financial Officer at Ingalls Shipbuilding

PASCAGOULA, Miss., Jan. 08, 2021 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE: HII) announced today that Keith Munn has been promoted to vice president, business management, and chief financial officer for Ingalls Shipbuilding. In his new role, he will be responsible for all financial management, contract management and business management functions at Ingalls.Munn will be located at HII’s Ingalls Shipbuilding division in Pascagoula, and will report to Ingalls Shipbuilding President Brian Cuccias. Munn replaces Tom Stiehle, who has been promoted to HII executive vice president and CFO. Munn will assume this new role on Feb. 15, 2021.“Keith’s extensive knowledge and accomplished background have been an asset to Ingalls for many years,” Cuccias said. “His experience positions him for success in this important role on our...

Continue reading

Ryman Hospitality Properties, Inc. Announces Fourth Quarter 2020 Earnings Conference Call – Friday, February 26th, 2021, 10 a.m. ET

NASHVILLE, Tenn., Jan. 08, 2021 (GLOBE NEWSWIRE) — Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”), a lodging real estate investment trust (“REIT”) specializing in group-oriented, destination hotel assets in urban and resort markets, announced today that it will release its fourth quarter 2020 earnings results before the market opens on Friday, February 26, 2021. Management will hold a conference call to discuss the quarter’s results at 10:00 a.m. ET of the same day.To participate in the conference call, please dial 973-935-8756 and use conference ID 7189891. The call will be available for replay through March 26, 2021 by dialing 800-585-8367 and using conference ID 7189891. This call is also being webcast and can be accessed at Ryman Hospitality Properties’ Investor Relations website at http://ir.rymanhp.com.About Ryman...

Continue reading

Herborium® Group Inc, Shareholders Update Letter

Fort Lee, New Jersey, Jan. 08, 2021 (GLOBE NEWSWIRE) — Herborium® Group, Inc. (OTC Pink: HBRM),  www.Herborium.com, www.acnease.com a Botanical Therapeutics® Company and the provider of proprietary all botanical medicinal products (Botanical Therapeutics®) and interactive advanced content targeting dermatological issues such as acne and Rosacea, and other health and wellness concerns, is happy to provide a Shareholders Update Letter  from Dr. Agnes Olszewski, CEO.To our Valued Shareholders,Happy and Healthy New Year!By now, when the most difficult year of 21st century can be seen in the rear mirror and we all look with hope to a pandemic free life it’s time to provide an update on the recent milestones we achieved and to discuss our opportunities and vision for 2021 and beyond.The world has changed and so has Herborium. To survive...

Continue reading

Merus reçoit de la FDA la désignation Fast Track pour le zénocutuzumab dans le cadre du traitement des patients atteints de cancer avec fusion du gène neuréguline-1

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 08 janv. 2021 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS), une société d’oncologie de stade clinique qui développe des anticorps multispécifiques pleine longueur (Biclonics® et Triclonics™) pour le traitement du cancer, a annoncé aujourd’hui que la Food and Drug Administration (FDA) des États-Unis avait accordé la désignation Fast Track au zénocutuzumab (Zeno) pour le traitement des patients atteints de tumeurs solides métastatiques hébergeant des fusions du gène NRG1 (cancers NRG1+) qui ont progressé avec un traitement standard.La désignation « Fast Track », octroyée par la FDA, a pour but de faciliter le développement et accélérer l’examen de médicaments visant à traiter de graves maladies et à répondre à un besoin médical non satisfait.Les fusions du gène NRG1...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.